Summary
Join us at the 37th Annual JP Morgan Healthcare Conference in San Francisco. To view details on Goodwin-sponsored events and attendees, see our JP Morgan minisite.
Related Content
- AlertApril 25, 2024
FTC Issues Final Rule Prohibiting Most Post-Employment Non-Compete Agreements
- Life Sciences PerspectivesApril 23, 2024
The European Parliament Adopts Position on the European Commission’s Proposal for the First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years
- Life Sciences PerspectivesApril 23, 2024
Recap: Goodwin Rare Disease Symposium 2024
- Big Molecule WatchApril 23, 2024
FDA Approval of Alvotech/Teva Ustekinumab Biosimilar
- Big Molecule WatchApril 22, 2024
DOJ Files False Claims Act Complaint Against Regeneron, Alleging Fraudulent Eylea Drug Pricing
- Big Molecule WatchApril 22, 2024
Federal Circuit Dismisses Appeals in Regeneron v. Mylan (Aflibercept) BPCIA Litigation
- AlertApril 22, 2024
The European Parliament Adopts Position on the European Commission’s Proposal for the First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years
- Big Molecule WatchApril 19, 2024
Fresenius Kabi Announces Launch of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRA
- Press ReleaseApril 23, 2024
Allurion Technologies Completes $48 Million Convertible Senior Secured Note Financing with RTW Investments
- Press ReleaseApril 22, 2024
Sound Bioventures joins £19 Million Financing of Theolytics
- In the PressApril 22, 2024
PowerUp 4 - Omer Tene (Spotify)
- Awards and RankingsApril 18, 2024
Goodwin is Number One in the Q1 2024 League Table Rankings
- Press ReleaseApril 18, 2024
Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval
- Press ReleaseApril 17, 2024
Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma
- Press ReleaseApril 16, 2024
Goodwin Represents the Underwriters in PACS Group $450 Million IPO
- Press ReleaseApril 15, 2024
Goodwin Advises Exclusive Placement Agent in Acrivon Therapeutics’ $130 Million Private Placement